Revance Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Crown Laboratories finalizes its acquisition of Revance Therapeutics, reinforcing its position in the aesthetics and skincare market.
Revance Therapeutics has agreed to a revised acquisition offer from Crown Laboratories, increasing the offer price to $3.65 per share and extending the tender offer deadline to February 4, 2025.
Revance Therapeutics has amended its merger agreement with Crown Laboratories to clarify the calculation of the Expiration Time.
Crown Laboratories will launch a tender offer to acquire Revance Therapeutics for $3.10 per share in cash, following an amended merger agreement.
Revance Therapeutics and Crown Laboratories have agreed to a further extension of the deadline for Crown to commence its tender offer for Revance shares, now set for December 9, 2024.
Revance Therapeutics has received approval in China for its cervical dystonia treatment and has further extended the tender offer commencement date to December 5, 2024.
8-K: Revance Therapeutics Merger Offer Delayed Again as Discussions with Crown Laboratories Continue
Revance Therapeutics and Crown Laboratories have agreed to a further extension of the tender offer commencement date to December 3, 2024, due to ongoing discussions.
Revance Therapeutics and Crown Laboratories have agreed to a ninth extension of the deadline for Crown to commence its tender offer to acquire Revance, now set for November 29, 2024.
Revance Therapeutics and Crown Laboratories have agreed to further extend the deadline for the commencement of the tender offer to November 26, 2024, marking the eighth such extension.
Revance Therapeutics and Crown Laboratories have agreed to extend the deadline for the commencement of the tender offer to November 19, 2024, marking the seventh such delay.
Revance Therapeutics announced its third quarter 2024 financial results, a merger agreement with Crown Laboratories, and an extension to the tender offer commencement date.
The tender offer for Revance Therapeutics by Crown Laboratories has been delayed again, now to November 12, 2024, due to ongoing discussions between the parties.
Revance Therapeutics has entered into new distribution agreements with Teoxane SA for Australia and New Zealand, while also extending the tender offer commencement date with Crown Laboratories.
Revance Therapeutics has further delayed the commencement of its merger tender offer due to ongoing discussions with Teoxane regarding a distribution agreement dispute.
Revance Therapeutics has further delayed the commencement of its merger tender offer due to ongoing discussions regarding a distribution agreement breach and merger agreement terms.
Revance Therapeutics is in discussions with Teoxane over alleged breaches of their distribution agreement, and has extended the commencement date of its merger tender offer with Crown Laboratories.
Revance Therapeutics' partner, Shanghai Fosun Pharmaceutical, has received approval from China's National Medical Products Administration for DaxibotulinumtoxinA for Injection to treat glabellar lines.
Revance Therapeutics and Crown Laboratories have agreed to extend the commencement date of the tender offer for Revance's shares from August 30, 2024, to September 13, 2024.
Crown Laboratories will acquire Revance Therapeutics for $6.66 per share in cash, creating a leading aesthetics and skincare company.
Revance Therapeutics clarified that its aesthetic portfolio includes over 8,000 accounts, with over 4,200 having ordered DAXXIFY, as of June 30, 2024.
Revance Therapeutics announced a 20% year-over-year increase in total revenue for the second quarter of 2024, driven by strong sales of DAXXIFY and the RHA Collection.
Revance Therapeutics announced its first quarter 2024 financial results, highlighted by a 13% year-over-year revenue increase and the commercial launch of DAXXIFY for cervical dystonia.
Revance Therapeutics held its 2024 annual meeting, electing three Class I directors, ratifying its auditor, and approving executive compensation on an advisory basis.
Revance Therapeutics has entered into an underwriting agreement for a public offering of 16 million shares of its common stock at $6.25 per share, aiming to raise approximately $100 million.
Revance Therapeutics reported strong year-over-year revenue growth for 2023, driven by increased sales of DAXXIFY and the RHA Collection, and provided a positive outlook for 2024.
Revance Therapeutics has updated its corporate objectives for 2024 and amended its executive severance plan, impacting bonus structures and severance benefits for key employees.
Revance Therapeutics has approved the 2024 bonus program and equity mix for its executive officers, with the CEO's bonus solely tied to corporate goals and other executives' bonuses including individual performance modifiers.